ABSK-021 is under clinical development by Abbisko Therapeutics and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast Cancer (TNBC) have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ABSK-021’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ABSK-021 is under development for the treatment of advanced malignancies, tenosynovial giant cell tumors (TGCT), pancreatic cancer, triple negative breast cancer, non-small cell lung cancer, small cell lung cancer and other solid tumors, chronic graft versus host disease (GvHD) and amyotrophic lateral sclerosis (ALS). The therapeutic candidate is formulated as capsule and administered through oral route. It is acts by targeting CSF1R.
Abbisko Therapeutics overview
Abbisko Therapeutics (Abbisko) is a biopharmaceutical company. It discovers and develops of novel medicines to the treatment of cancers and other diseases. Its pipeline immuno-oncology small molecule modulators include ABSK011, ABSK021, ABSK003, ABSK004, and ABSK005 reactivating tumor-specific immune response and human immune system to fight against cancer cells; ABSK006 for the treatment of diabetes. It owns an integrated research and development center in Shanghai Zhangjiang Hi-Tech Park to conduct immune-oncology drug development activities. The company is funded by healthcare investors such as Lilly Asia Ventures, Sinopharm Capital, Jianxin Capital, and TF Capital. Abbisko is headquartered in Shanghai, China.
For a complete picture of ABSK-021’s drug-specific PTSR and LoA scores, buy the report here.